| Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
|---|---|---|---|---|---|
Gross Sales | 6,446.49 | 6,259.69 | 6,407.89 | 5,943.51 | 5,655.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,446.49 | 6,259.69 | 6,407.89 | 5,943.51 | 5,655.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 254.79 | 181.81 | 129.03 | 114 | 102.08 |
Total Income | 6,701.28 | 6,441.5 | 6,536.92 | 6,057.51 | 5,757.83 |
Total Expenditure | 5,085.02 | 5,213.95 | 5,329.63 | 5,094.19 | 4,998.6 |
PBIDT | 1,616.26 | 1,227.55 | 1,207.29 | 963.32 | 759.23 |
Interest | 57.25 | 52.32 | 60.09 | 56.01 | 51.35 |
PBDT | 1,559.01 | 1,175.23 | 1,147.2 | 907.31 | 707.88 |
Depreciation | 159.39 | 152.99 | 146.31 | 156.76 | 153.66 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 280.31 | 197.45 | 224.83 | 152 | 121.9 |
Deferred Tax | -132.89 | -83.97 | -126.64 | 70.91 | -46.85 |
Reported Profit After Tax | 1,252.2 | 908.76 | 902.7 | 527.64 | 479.17 |
Minority Interest After NP | 18.4 | 20.24 | -4.55 | 1.95 | 20.69 |
Net Profit after Minority Interest | 1,233.8 | 888.52 | 907.25 | 525.69 | 458.48 |
Extra-ordinary Items | 0 | -63.83 | -44.71 | -102.98 | 0 |
Adjusted Profit After Extra-ordinary item | 1,233.8 | 952.35 | 951.96 | 628.67 | 458.48 |
EPS (Unit Curr.) | 103.2 | 74.32 | 75.88 | 43.97 | 38.35 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 25.07 | 19.61 | 18.84 | 16.2 | 13.42 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 19.42 | 14.51 | 14.08 | 8.87 | 8.47 |
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
